A randomized controlled trial of two schedules of hepatitis B vaccination in predialysed chronic renal failure patients

Hepatitis Monthly

Volumn 12, Issue 5, 2012, Pages 344-348

  Ahmadi, Farokhlagha ^a   Ramezani, Morteza ^a   Razeghi, Effat ^b   Ranjbarnovin, Neda ^a   Khazaeipour, Zahra ^a,c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Chronic; Hepatitis B; Kidney failure; Vaccination

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CREATININE; FERRITIN; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PARATHYROID HORMONE; RECOMBINANT HEPATITIS B VACCINE;

ADULT; ANTIBODY TITER; ARTICLE; BODY WEIGHT; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DRUG DOSE COMPARISON; ENZYME IMMUNOASSAY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HEMODIALYSIS PATIENT; HEPATITIS B; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION;

EID: 84862588311     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: 10.5812/hepatmon.6438     Document Type: Article

References (32)

1. Tang S, Lai KN. Chronic viral hepatitis in hemodialysis patients. Hemodial Int. 2005;9(2):169-79.
2. Recommendation of the Immunization Practices Advisory Committee (ACIP). Inactivated hepatitis B virus vaccine. MMWR Morb Mortal Wkly Rep. 1982;31(24):317-22, 27-8.
3. van Dijk PC, Jager KJ, de Charro F, Collart F, Cornet R, Dekker FW, et al. Renal replacement therapy in Europe: the results of a collaborative effort by the ERA-EDTA registry and six national or regional registries. Nephrol Dial Transplant. 2001;16(6):1120-9.
4. Johnson DW, Fleming SJ. The use of vaccines in renal failure. Clin Pharmacokinet. 1992;22(6):434-46.
5. Finelli L, Miller JT, Tokars JI, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial. 2005;18(1):52-61.
6. Infection control requirements for dialysis facilities and clarification regarding guidance on parenteral medication vials. MMWR Morb Mortal Wkly Rep. 2008;57(32):875-6.
7. Peces R, de la Torre M, Alcazar R, Urra JM. Prospective analysis of the factors influencing the antibody response to hepatitis B vaccine in hemodialysis patients. Am J Kidney Dis. 1997;29(2):239-45.
8. Pesanti EL. Immunologic defects and vaccination in patients with chronic renal failure. Infect Dis Clin North Am. 2001;15(3):813-32.
9. Docci D, Cipolloni PA, Mengozzi S, Baldrati L, Capponcini C, Feletti C. Immunogenicity of a recombinant hepatitis B vaccine in hemodialysis patients: a two-year follow-up. Nephron. 1992;61(3):352-3.
10. Mitwalli A. Responsiveness to hepatitis B vaccine in immunocompromised patients by doubling the dose scheduling. Nephron. 1996;73(3):417-20.
11. Fabrizi F, Dixit V, Magnini M, Elli A, Martin P. Meta-analysis: intradermal vs. intramuscular vaccination against hepatitis B virus in patients with chronic kidney disease. Aliment Pharmacol Ther. 2006;24(3):497-506.
12. Brodersen HP, Holtkamp W, Larbig D, Beckers B, Thiery J, Lautenschlager J, et al. Zinc supplementation and hepatitis B vaccination in chronic haemodialysis patients: a multicentre study. Nephrol Dial Transplant. 1995;10(9):1780.
13. Argani H, Akhtarishojaie E. Levamizole enhances immune responsiveness to intra-dermal and intra-muscular hepatitis B vaccination in chronic hemodialysis patients. J Immune Based Ther Vaccines. 2006;4:3.
14. Quiroga JA, Castillo I, Porres JC, Casado S, Saez F, Gracia Martinez M, et al. Recombinant gamma-interferon as adjuvant to hepatitis B vaccine in hemodialysis patients. Hepatology. 1990;12(4 Pt 1):661-3.
15. Jungers P, Devillier P, Salomon H, Cerisier JE, Courouce AM. Randomised placebo-controlled trial of recombinant interleukin-2 in chronic uraemic patients who are non-responders to hepatitis B vaccine. Lancet. 1994;344(8926):856-7.
16. Verkade MA, van de Wetering J, Klepper M, Vaessen LM, Weimar W, Betjes MG. Peripheral blood dendritic cells and GM-CSF as an adjuvant for hepatitis B vaccination in hemodialysis patients. Kidney Int. 2004;66(2):614-21.
17. Rangel MC, Coronado VG, Euler GL, Strikas RA. Vaccine recommendations for patients on chronic dialysis. The Advisory Committee on Immunization Practices and the American Academy of Pediatrics. Semin Dial. 2000;13(2):101-7.
18. Chow KM, Law MC, Leung CB, Szeto CC, Li PK. Antibody response to hepatitis B vaccine in end-stage renal disease patients. Nephron Clin Pract. 2006;103(3):c89-93.
19. Dukes CS, Street AC, Starling JF, Hamilton JD. Hepatitis B vaccination and booster in predialysis patients: a 4-year analysis. Vaccine. 1993;11(12):1229-32.
20. Seaworth B, Drucker J, Starling J, Drucker R, Stevens C, Hamilton J. Hepatitis B vaccines in patients with chronic renal failure before dialysis. J Infect Dis. 1988;157(2):332-7.
21. Bel'eed K, Wright M, Eadington D, Farr M, Sellars L. Vaccination against hepatitis B infection in patients with end stage renal disease. Postgrad Med J. 2002;78(923):538-40.
22. McNulty CA, Bowen JK, Williams AJ. Hepatitis B vaccination in predialysis chronic renal failure patients a comparison of two vaccination schedules. Vaccine. 2005;23(32):4142-7.
23. Waite NM, Thomson LG, Goldstein MB. Successful vaccination with intradermal hepatitis B vaccine in hemodialysis patients previously nonresponsive to intramuscular hepatitis B vaccine. J Am Soc Nephrol. 1995;5(11):1930-4.
24. Chang PC, Schrander-van der Meer AM, van Dorp WT, van Leer E. Intracutaneous versus intramuscular hepatitis B vaccination in primary non-responding haemodialysis patients. Nephrol Dial Transplant. 1996;11(1):191-3.
25. Rosman AS, Lieber CS. Improving the response to hepatitis B vaccine. Infect Med. 1999;16:205-1810.
26. Agarwal SK, Irshad M, Dash SC. Comparison of two schedules of hepatitis B vaccination in patients with mild, moderate and severe renal failure. J Assoc Physicians India. 1999;47(2):183-5.
27. Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G. Meta-analysis: the effect of age on immunological response to hepatitis B vaccine in end-stage renal disease. Aliment Pharmacol Ther. 2004;20(10):1053-1062.
28. Hashemi B, Mahdavi-Mazdeh M, Abbasi M, Hosseini-Moghaddam SM, Zinat NH, Ahmadi F. Efficacy of HBV vaccination in various stages of chronic kidney disease: is earlier better? Hepat Mon. 2011;11(10):816-20.
29. Fraser GM, Ochana N, Fenyves D, Neumann L, Chazan R, Niv Y, et al. Increasing serum creatinine and age reduce the response to hepatitis B vaccine in renal failure patients. J Hepatol. 1994;21(3):450-4.
30. DaRoza G, Loewen A, Djurdjev O, Love J, Kempston C, Burnett S, et al. Stage of chronic kidney disease predicts seroconversion after hepatitis B immunization: earlier is better. Am J Kidney Dis. 2003;42(6):1184-92.
31. Edey M, Barraclough K, Johnson DW. Review article: Hepatitis B and dialysis. Nephrology (Carlton). 2010;15(2):137-45.
32. Joukar F, Besharati S, Mirpour H, Mansour-Ghanaei F. Hepatitis C and hepatitis B seroprevalence and associated risk factors in hemodialysis patients in Guilan province, north of Iran: HCV and HBV seroprevalence in hemodialysis patients. Hepat Mon. 2011;11(3):178-81.